DGX has a higher market value than 88.8% of US stocks; more precisely, its current market capitalization is $16,143,176,246.
With a one year PEG ratio of 564.28, Quest Diagnostics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 93.75% of US stocks.
Of note is the ratio of Quest Diagnostics Inc's sales and general administrative expense to its total operating expenses; 98.31% of US stocks have a lower such ratio.
Stocks with similar financial metrics, market capitalization, and price volatility to Quest Diagnostics Inc are HUBB, MKC, WRK, MIDD, and IEX.
Quest Diagnostics provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices, analytic, on-site prevention, and wellness services, and risk assessment services for the life insurance industry. The company was founded in 1967 and is founded in Madison, New Jersey.
DGX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for DGX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Quest Diagnostics Inc ranked in the 39th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for DGX, they are:
As a business, DGX is generating more cash flow than 76.33% of positive cash flow stocks in the Healthcare.
Quest Diagnostics Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than only 14.75% of tickers in our DCF set.
DGX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than only 14.75% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
STE, PAHC, BDX, CNC, and EBS can be thought of as valuation peers to DGX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
SECAUCUS, N.J., Sept. 30, 2020 /PRNewswire/ -- Healthcare providers across the United States can now access three different test options from Quest Diagnostics (NYSE: DGX) to aid the diagnosis of COVID-19 and differentiate it from other seasonal respiratory infections, including influenza…
Quest Diagnostics has launched a 3-in-1 COVID-19 test that will work from a single swab. Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Anjalee Khemlani discuss the test, and the latest details in the race for a vaccine.
Summary List Placement Retail behemoth Walmart is teaming up with clinical lab giant Quest Diagnostics to test delivering coronavirus nasal swab kits via drones to eligible homes in Las Vegas and Cheektowaga, New York. To participate, customers must reside within a 1-mile radius of a Walmart store in these regions and mail in the completed nasal swab to Quest Diagnostics for their test results. Walmart's latest move highlights how retail pharmacies have leveraged drone delivery during the pandemic—but we think it will have limited utility in the broader healthcare space. For instance, CVS made similar moves earlier this year when it partnered with UPS to offer Florida retirement facilities drone delivery for prescription drugs. However, drone manufacturers must overcome a number of regu...
DUBLIN--(BUSINESS WIRE)--The "Global Helicobacter Pylori Diagnostics Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The helicobacter pylori diagnostics market is poised to grow by $ 209.59 million during 2020-2024 progressing at a CAGR of 8% during the forecast period. The reports on helicobacter pylori diagnostics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 ve